

Date: April 27, 2020

To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, BSE Limited, 1 st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
Scrip Code - LINCOLN	Scrip Code - 531633

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Press Release titled "Lincoln Pharmaceuticals Limited receives approval to manufacture Hydroxychloroquine and Hydroxychloroquine Sulfate Tablets to fight COVID 19".

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,
FOR LINCOLN PHARMACEUTICALS LIMITED

Sd/-
NIREN A. DESAI
[COMPANY SECRETARY]

Encl: a/a

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, [Guj.] | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



Media Release

Lincoln Pharmaceuticals Limited receives approval to manufacture Hydroxychloroquine and Hydroxychloroquine Sulfate Tablets to fight COVID 19

April 27, 2020: Lincoln Pharmaceuticals Limited (“Lincoln Pharma”), one of India's leading healthcare companies has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. Company received approval from Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj in Ahmedabad. After necessary approval from Directorate General of Foreign Trade (DGFT) company will be able to export these products.

Food & Drug Control Administration, Gujarat approved manufacture of following drugs from Lincoln Pharma's Khatraj facility.

- Hydroxychloroquine Sulfate Tablets USP in 200 MG, 300 MG and 400 MG dosages.
- Hydroxychloroquine Tablets IP in 200 MG, 300 MG and 400 MG dosages respectively.

Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "We have all the necessary infrastructure at our state-of-the-art manufacturing facility at Khatraj, Ahmedabad and look to expedite the commercial production of the approved drugs at the earliest. Company is committed to fight the COVID-19 pandemic and working closely with the governments and relevant stakeholders to ensure uninterrupted supply of medicines. Company has also constituted a task force to handle the distribution of medicines and essential drugs with the primary objective of dealing with any kind of emergency or distress situation by COVID-19."

HCQ is a prescription based drug commonly recommended to Corona patients under treatment for the disease. India is the largest producer of HCQ and taking a lead in supplying this to the world in this time of crisis.

Lincoln Pharmaceuticals Limited develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filled 20 plus patent applications and is awarded five patents. Company has presence in more than 60 countries encompassing Africa, Central America and Southeast Asia. Company is building a strong portfolio in lifestyle and chronic segment especially in women healthcare and dermatology to complement our strong presence in acute segment.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, [Guj.] | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com



About Lincoln Pharmaceuticals Limited: <https://www.lincolnpharma.com/>

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 300 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company markets its products in the Indian market and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create **“Healthcare for All”**.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 20 plus patent applications and is awarded five patents. R&D center of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop with a capacity of producing 15 Lakh Power Unit Per annum in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization. Company's long term ratings are revised from A-/stable to A-/positive and short term rating A2+ by ICRA.

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, [Guj.] | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com

